How the development of new biological agents may help minimize immunosuppression in kidney transplantation: The impact of belatacept

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Purpose of Review: The purpose of this review is to discuss the use of belatacept as part of an immunosuppression regimen in renal transplant recipients to avoid the renal and nonrenal toxicities associated with calcineurin inhibitors (CNIs). Recent Findings: Current immunosuppression protocols utilize CNIs that are associated with renal and cardiovascular/ metabolic toxicities. Belatacept, a selective costimulation blocker, is designed to provide effective immunosuppression while avoiding the toxicities associated with CNIs. Phase III trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Two-year data demonstrate up to a 17 ml/min/1.73 m2 improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Belatacept-treated patients had better blood pressure control and lipid profiles compared to cyclosporine-treated patients. There were more cases of posttransplant lymphoproliferative disease in belatacept-treated patients, especially in Epstein-Barr virus-negative recipients or patients treated with lymphocyte-depleting agents. In a conversion trial from a CNI to belatacept, the mean increase in renal function was 7.0 and 2.1 ml/min/1.73 m2 in the belatacept and cyclosporine groups, respectively. Summary: Belatacept provides effective immunosuppression while avoiding or minimizing the untoward side effects seen with CNIs. Conversion from a CNI to belatacept posttransplantation appears to be safe and effective and results in improved renal allograft function. Data suggest that belatacept use may eventually lead to improved long-term allograft survival and decrease the overall long-term mortality by improving the cardiovascular and metabolic profile of renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)697-702
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume15
Issue number6
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Biological Factors
Kidney Transplantation
Immunosuppression
Kidney
Cyclosporine
Allografts
Abatacept
Metabolome
Human Herpesvirus 4
Glomerular Filtration Rate
Calcineurin Inhibitors
Lymphocytes
Blood Pressure
Lipids

Keywords

  • belatacept
  • calcineurin inhibitor avoidance
  • kidney transplant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

@article{563d00caf65048be84a09c47a15bc002,
title = "How the development of new biological agents may help minimize immunosuppression in kidney transplantation: The impact of belatacept",
abstract = "Purpose of Review: The purpose of this review is to discuss the use of belatacept as part of an immunosuppression regimen in renal transplant recipients to avoid the renal and nonrenal toxicities associated with calcineurin inhibitors (CNIs). Recent Findings: Current immunosuppression protocols utilize CNIs that are associated with renal and cardiovascular/ metabolic toxicities. Belatacept, a selective costimulation blocker, is designed to provide effective immunosuppression while avoiding the toxicities associated with CNIs. Phase III trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Two-year data demonstrate up to a 17 ml/min/1.73 m2 improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Belatacept-treated patients had better blood pressure control and lipid profiles compared to cyclosporine-treated patients. There were more cases of posttransplant lymphoproliferative disease in belatacept-treated patients, especially in Epstein-Barr virus-negative recipients or patients treated with lymphocyte-depleting agents. In a conversion trial from a CNI to belatacept, the mean increase in renal function was 7.0 and 2.1 ml/min/1.73 m2 in the belatacept and cyclosporine groups, respectively. Summary: Belatacept provides effective immunosuppression while avoiding or minimizing the untoward side effects seen with CNIs. Conversion from a CNI to belatacept posttransplantation appears to be safe and effective and results in improved renal allograft function. Data suggest that belatacept use may eventually lead to improved long-term allograft survival and decrease the overall long-term mortality by improving the cardiovascular and metabolic profile of renal transplant recipients.",
keywords = "belatacept, calcineurin inhibitor avoidance, kidney transplant",
author = "David Wojciechowski and Flavio Vincenti",
year = "2010",
month = "12",
day = "1",
doi = "10.1097/MOT.0b013e3283402b5c",
language = "English (US)",
volume = "15",
pages = "697--702",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - How the development of new biological agents may help minimize immunosuppression in kidney transplantation

T2 - The impact of belatacept

AU - Wojciechowski, David

AU - Vincenti, Flavio

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose of Review: The purpose of this review is to discuss the use of belatacept as part of an immunosuppression regimen in renal transplant recipients to avoid the renal and nonrenal toxicities associated with calcineurin inhibitors (CNIs). Recent Findings: Current immunosuppression protocols utilize CNIs that are associated with renal and cardiovascular/ metabolic toxicities. Belatacept, a selective costimulation blocker, is designed to provide effective immunosuppression while avoiding the toxicities associated with CNIs. Phase III trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Two-year data demonstrate up to a 17 ml/min/1.73 m2 improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Belatacept-treated patients had better blood pressure control and lipid profiles compared to cyclosporine-treated patients. There were more cases of posttransplant lymphoproliferative disease in belatacept-treated patients, especially in Epstein-Barr virus-negative recipients or patients treated with lymphocyte-depleting agents. In a conversion trial from a CNI to belatacept, the mean increase in renal function was 7.0 and 2.1 ml/min/1.73 m2 in the belatacept and cyclosporine groups, respectively. Summary: Belatacept provides effective immunosuppression while avoiding or minimizing the untoward side effects seen with CNIs. Conversion from a CNI to belatacept posttransplantation appears to be safe and effective and results in improved renal allograft function. Data suggest that belatacept use may eventually lead to improved long-term allograft survival and decrease the overall long-term mortality by improving the cardiovascular and metabolic profile of renal transplant recipients.

AB - Purpose of Review: The purpose of this review is to discuss the use of belatacept as part of an immunosuppression regimen in renal transplant recipients to avoid the renal and nonrenal toxicities associated with calcineurin inhibitors (CNIs). Recent Findings: Current immunosuppression protocols utilize CNIs that are associated with renal and cardiovascular/ metabolic toxicities. Belatacept, a selective costimulation blocker, is designed to provide effective immunosuppression while avoiding the toxicities associated with CNIs. Phase III trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Two-year data demonstrate up to a 17 ml/min/1.73 m2 improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Belatacept-treated patients had better blood pressure control and lipid profiles compared to cyclosporine-treated patients. There were more cases of posttransplant lymphoproliferative disease in belatacept-treated patients, especially in Epstein-Barr virus-negative recipients or patients treated with lymphocyte-depleting agents. In a conversion trial from a CNI to belatacept, the mean increase in renal function was 7.0 and 2.1 ml/min/1.73 m2 in the belatacept and cyclosporine groups, respectively. Summary: Belatacept provides effective immunosuppression while avoiding or minimizing the untoward side effects seen with CNIs. Conversion from a CNI to belatacept posttransplantation appears to be safe and effective and results in improved renal allograft function. Data suggest that belatacept use may eventually lead to improved long-term allograft survival and decrease the overall long-term mortality by improving the cardiovascular and metabolic profile of renal transplant recipients.

KW - belatacept

KW - calcineurin inhibitor avoidance

KW - kidney transplant

UR - http://www.scopus.com/inward/record.url?scp=78649684946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649684946&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e3283402b5c

DO - 10.1097/MOT.0b013e3283402b5c

M3 - Review article

C2 - 20930638

AN - SCOPUS:78649684946

VL - 15

SP - 697

EP - 702

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 6

ER -